A Randomized, Multicentre, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
In this study, all patients must have already completed first-line chemotherapy to treat
extensive-stage disease small cell lung cancer. The purpose of this study is to show that
Nivolumab, or Nivolumab plus Ipilimumab followed by Nivolumab by itself, will prolong
overall survival and progression free survival when administered as consolidation treatment
in patients that are stable or responding after chemotherapy. Patients receiving treatment
will be compared with patients taking placebo.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society